일부 국가의 의약품 재정영향분석 가이드라인의 비교 분석을 통한 국내 도입 시사점: 캐나다, 폴란드, 아일랜드, 벨기에 사례를 중심으로
Comparative Study on Budget Impact Analysis Guideline of Canada, Poland, Belgium and Ireland
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives: This study explored national Budget Impact Analysis (BIA) guideline and analysed commonalities and differences among them. Methods: We compared the contents of national BIA guidelines developed in Poland (2005), Canada (2007), Belgium (2008/2010), and Ireland (2010/2014). Results: Budget Impact Analysis (BIA) guidelines were explained and analysed with the items of context of development and participants, scope of analysis and expected usage, perspective, model, time horizon and characteristics of drugs, target population and data sources, cost calculation and resource reallocation, results and uncertainty and sensitivity analysis, inflation, discount rate and etc. Conclusion: In Korea, pharmaceutical companies should submit BIA as a part of the pharmacoeconomics which is requirement for listing new drug under positive list system, since December 2006. It is important to develop BIA guideline separately from the pharmacoeconomics guideline to advance transparency in decision making process.
Abstract
Objectives: This study explored national Budget Impact Analysis (BIA) guideline and analysed commonalities and differences among them. Methods: We compared the contents of national BIA guidelines developed in Poland (2005), Canada (2007), Belgium (2008/2010), and Ireland (2010/2014). Results: Budget Impact Analysis (BIA) guidelines were explained and analysed with the items of context of development and participants, scope of analysis and expected usage, perspective, model, time horizon and characteristics of drugs, target population and data sources, cost calculation and resource reallocation, results and uncertainty and sensitivity analysis, inflation, discount rate and etc. Conclusion: In Korea, pharmaceutical companies should submit BIA as a part of the pharmacoeconomics which is requirement for listing new drug under positive list system, since December 2006. It is important to develop BIA guideline separately from the pharmacoeconomics guideline to advance transparency in decision making process.
참고문헌 (14)
- Mauskopf JA, "Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis", Value Health, 10, pp.336~347 (2007)
- Mauskopf J, "Prevalence-based economic evaluation", Value Health, 1, pp.251~259 (1998)
- Mauskopf JA, "Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis", Value Health, 10, pp.336~347 (2007)
- Neumann PJ, "Budget impact analyses get some respect", Value Health, 10, pp.324~325 (2007)
- Trueman P, "Developing guidance for budget impact analysis", Pharmacoeconomics, 19, pp.609~621 (2001)
- Orlewska E, "Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries", Value Health, 7, pp.1~10 (2004)
- Sullivan SD, "Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force", Value Health, 17, pp.5~14 (2014)
- "Guidelines for the Budget Impact Analysis of Health Technologies in Ireland" (2010)[URL]
- "Guidelines for the Budget Impact Analysis of Health Technologies in Ireland" (2014)[URL]
- 김정주, "약가연동제·재정영향분석 등 협상기전 도마위", 데일리팜, ~ (2011)
- 김성옥, "의약품 재정영향분석 가이드라인의 개발 요구 평가", 보건경제와 정책연구, 15(1), pp.107~130 (2009), 한국보건경제정책학회
- 협상대상 의약품의 재정영향분석 사례연구, "김영숙", 국민건강보험공단, 45~46 (2009)
- Patented Medicine Prices Review Board, "Budget Impact Analysis Guidelines: Needs Assessment (National Prescription Drug Utilization Information System Analytical Study Series)", 9~ (2005)
- Belgian Guidelines For Economic Evaluations and Budget Impact Analyses: Second Edition, "Cleemput I", KCE, ~, pp.KCE Report 183C